Literature DB >> 17143975

Why are only 50% of courses of anti-tumor necrosis factor agents continued for only 2 years in some settings? Need for longterm observations in standard care to complement clinical trials.

Theodore Pincus, Yusuf Yazici, Ronald van Vollenhoven.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17143975

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


× No keyword cloud information.
  3 in total

1.  Is there a place for nonbiological drugs in the treatment of rheumatoid arthritis?

Authors:  Alejandro Balsa; Miriam García-Arias
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-12       Impact factor: 5.346

2.  Biologic agents-a panacea for inflammatory arthritis or not?

Authors:  J Ninan; Malcolm D Smith; M Dugar; Karen O'Brien; Michael Ahern
Journal:  Int J Rheumatol       Date:  2009-12-08

3.  A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post-hoc results from the certolizumab pegol phase 4 PREDICT trial.

Authors:  Jeffrey R Curtis; Christopher Herrem; 'Matladi N Ndlovu; Cathy O'Brien; Yusuf Yazici
Journal:  Arthritis Res Ther       Date:  2017-09-29       Impact factor: 5.156
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.